Showing results (1-10 of 1,359) with videos related to

Sort By:
Pageof 136
Brain Pathology (Zurich, Switzerland)|April 13, 2017
Axonal loss in the multiple sclerosis spinal cord revisitedNatalia Petrova, Daniele Carassiti, Daniel R Altmann, et al.
Annals of Neurology|July 2, 2020
Synaptic Loss in Multiple Sclerosis Spinal CordNatalia Petrova, Erik Nutma, Daniele Carassiti, et al.
Magnetic Resonance in Medicine|January 11, 2022
High-resolution quantitative MRI of multiple sclerosis spinal cord lesionsAmy R McDowell, Natalia Petrova, Daniele Carassiti, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatmentDavid Baker, Gavin Giovannoni, Klaus Schmierer
Multiple Sclerosis and Related Disorders|March 20, 2015
The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?Gavin Giovannoni, David Baker, Klaus Schmierer
Current Opinion in Neurology|April 12, 2021
Highly effective disease-modifying treatment as initial MS therapyKlaus Schmierer, Per S Sørensen, David Baker
Magnetic Resonance in Medicine|June 16, 2017
Assessment of ferritin content in multiple sclerosis brains using temperature-induced R*2 changesChristoph Birkl, Daniele Carassiti, Fariha Hussain, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2015
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineJulia Pakpoor, Giulio Disanto, Daniel R Altmann, et al.
Annals of Neurology|September 7, 2004
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brainKlaus Schmierer, Francesco Scaravilli, Daniel R Altmann, et al.
Multiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.
Pageof 136